Abciximab International Brand (Medicinal Forms)


Abciximab International Brand (Medicinal Forms)


INDICATIONS AND DOSE:

Prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (specialist use only)
INITIALLY BY INTRAVENOUS INJECTION
Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. per dose 10 micrograms/minute), to be started 10–60 minutes before percutaneous coronary intervention and continue for 12 hours
Short-term prevention of myocardial infarction in patients with unstable angina not responding to conventional treatment and who are scheduled for percutaneous coronary intervention (specialist use only)
INITIALLY BY INTRAVENOUS INJECTION
Adult: Initially 250 micrograms/kg, to be given over 1 minute, then (by intravenous infusion) 125 nanograms/kg/minute (max. per dose 10 micrograms/minute), to be started up to 24 hours before possible percutaneous coronary intervention and continue infusion for 12 hours after intervention

CONTRA-INDICATIONS

Active internal bleeding . arteriovenous malformation or aneurysm . haemorrhagic   diathesis . hypertensive retinopathy . intracranial neoplasm . intracranial or intraspinal surgery or trauma within last 2 months . major surgery within last 2 months . severe hypertension . stroke within last 2 years . thrombocytopenia . vasculitis

CAUTIONS

Discontinue if uncontrollable serious bleeding occurs or emergency cardiac surgery needed (consult product literature for details of procedures to minimize bleeding). elderly

SIDE-EFFECTS

Common or very common Back pain . bleeding manifestations . bradycardia . chest pain . fever . headache . hypotension . nausea . puncture site pain . thrombocytopenia . vomiting
Rare Adult respiratory distress . cardiac tamponade .hypersensitivity reactions

International Brands (Medicinal Forms)

Sr. #
Brand Name
Dosage Form
Pack Size
Price
Manufacturer
1.
ReoPro
Solution for injection-
Abciximab 2 mg per 1 ml
1 vial
£250.24
Janssen-Cilag Ltd


Reference:

No comments:

Post a Comment